A5102709027- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Mitochondrial Function and Pathology
- Liver Disease Diagnosis and Treatment
- Congenital heart defects research
- Endoplasmic Reticulum Stress and Disease
- Nitric Oxide and Endothelin Effects
- Glycosylation and Glycoproteins Research
- Galectins and Cancer Biology
- Single-cell and spatial transcriptomics
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Drug-Induced Hepatotoxicity and Protection
- Cytomegalovirus and herpesvirus research
- Acute Lymphoblastic Leukemia research
- Liver Disease and Transplantation
- CRISPR and Genetic Engineering
- Cardiac pacing and defibrillation studies
- Autophagy in Disease and Therapy
- Ferroptosis and cancer prognosis
- Cancer Immunotherapy and Biomarkers
Jiangsu Province Hospital
2020-2025
Nanjing Medical University
2018-2025
Taizhou People's Hospital
2025
Nantong University
2025
Wuxi People's Hospital
2020
Nanjing Drum Tower Hospital
2019-2020
In this study, we focused on gaining an in-depth understanding the attitudes and perceptions of hepatology healthcare professionals toward screening for cryptogenic hepatic encephalopathy (CHE), with goal providing references scientific standardized implementation CHE screening. Based phenomenological research method, semi-structured interviews nine medical were conducted in March 2023 at department a tertiary hospital Taizhou city. The collected data was then integrated analyzed using...
Complement component C3, mainly synthesized by hepatocytes, acts as the convergence point of three different pathways in activating complement cascade. Besides its well-established roles extracellular milieu, C3 performs various intracellular functions such immunomodulation and pathogen recognition. Although is present at extremely high concentrations little known about intrahepatic function. In this study, we found that knockout (C3-/- ) mice displayed accelerated hepatic triglyceride (TG)...
Increasing evidence has indicated an association between immune cell infiltration in lung adenocarcinoma (LUAD) and clinical outcomes.This study aimed to investigate the effect of 22 tumor-infiltrating cells (TIICs) on prognosis patients with LUAD.This was a case-control study.The CIBERSORT algorithm calculated proportion cases from Cancer Genome Atlas (TCGA) cohort. Cox regression analysis evaluated TIICs LUAD. The risk score model constructed based statistical correlation. Multivariate cox...
Rationale: Invariant natural killer T (iNKT) cells and Kupffer represent major hepatic populations of innate immune cells. However, their roles in steatohepatitis remain poorly understood. To elucidate functions development, real-time, vivo analysis is necessary to understand the pathophysiological events dynamic interactions between them during diet-induced steatohepatitis. Methods: We used a animal model induced by methionine-choline-deficient (MCD) diet. Multi-photon confocal live imaging...
Abstract Indolent lymphoma, including chronic lymphocytic leukemia/small lymphoma (CLL/SLL) and follicular (FL), can undergo histological transformation into an aggressive subtype, typically diffuse large B-cell (DLBCL). The prognosis of transformed is poor. In this study, we reported the efficacy toxicity a combination venetoclax, dose-adjusted rituximab or obinutuzumab, etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide (VR-DA-EPOCH VG-DA-EPOCH) in 11 patients with...
Introduction: To evaluate the safety and efficacy of Zanubrutinib Plus Bendamustine CD20 monoclonal antibody As Treatment for Mantle Cell Lymphoma patients. Methods: We analyzed 15 MCL patients aged who received ZBR/G as treatment in our cohort between July 2020 to March 2023. 12(80%) their initial treatment, while 3 2nd line treatment. Oral was given continuously (160 mg twice a day) from day 0, then intravenously rituximab (375 mg/m2 0) or Obinutuzumab (1000 0), (70 mg/m2, days 1–2), every...
Chronic lymphocytic leukemia (CLL) is the most common in Western world with great heterogeneity. Pyroptosis has recently been recognized as an inflammatory form of programmed cell death (PCD) and shares a close relationship apoptosis. Although role apoptosis CLL was comprehensively studied successfully applied clinical treatment, between pyroptosis genes remained largely unknown. In this study, eight differentially expressed pyroptosis-related (PRGs) were identified normal B cells. order to...
Objective: To compare the prognostic value of four models in predicting time to first treatment (TTFT) patients with Binet A Chinese chronic lymphocytic leukemia (CLL) . Methods: This retrospective analysis included one hundred and ten CLL, initially diagnosed First Affiliated Hospital Nanjing Medical University (Pukou CLL center) from June 2009 January 2020. Risk stratification was conducted according IPS-E, CLL-IPI, CLL1-PM, Barcelona-Brno models. Results: Among 110 patients, median age 58...
Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients diagnoses at First Affiliated Hospital Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage IGHV-D-J rearrangement pattern diagnosed CLL/SLL transformed diffuse large B-cell lymphoma (DLBCL) compared determine relatedness. risk...
Introduction: To evaluate the safety and efficacy of zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as treatment for DLBCL patients, we conducted this single-arm retrospective observational study. Methods: We enrolled patients aged 18 to 75 years old with high-risk DLBCL. Oral zanubrutinib was given continuously (160mg twice daily) from Day 0, 25mg daily 1-7. Patients were administered intravenously rituximab (375mg/m2 0), cyclophosphamide (750mg/m2 1), doxorubicin (50mg/m2 vincristine...
Abstract Time-limited treatment strategies in first line of chronic lymphocytic leukemia/small leukemia (CLL/SLL) were comprehensively explored. Thirty-four previously untreated, young fit CLL/SLL patients who initiated iFCR regimen between January 2019 and Match 2021 included our cohort. administered every 28-day cycle, with a maximum six cycles. Patients achieved complete remission or incomplete recovery (CR/CRi) bone marrow (BM) undetectable minimal residual disease (uMRD) 2 years after...
Aims: To evaluate the safety and efficacy of zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as first-line treatment for non-GCB DLBCL patients, we updated results in our cohort. Methods: We enrolled patients aged 18–75 with high-risk (including double expression other molecular characteristics). Oral zanubrutinib was given continuously (160 mg twice daily) from Day 0, 25 daily 1–7. Patients were administered intravenously rituximab (375 mg/m2 0), cyclophosphamide (750 1), doxorubicin (50...
Introduction: BTK inhibitors (BTKi) monotherapy has introduced the concept of continuous treatment in CLL/SLL until disease progression, leading to several concerns like lack deep remission, increasing risk toxic effects and substantial cost. Therefore, time-limited strategies as first line were comprehensively explored BTKi combined with chemoimmunotherapy was one these options which could induce durable responses young fit patients. Methods: patients who treated iFCR initial therapy First...
Introduction: Acquired BTK/PLCG2 mutations remain to be the driver of drug resistance. The underlying mechanisms need further explored. In this study, we retrospectively analyzed clinical and biological characteristics fifty-five BTKi-resistant CLL patients in our center mapped mutational landscape. Method: Fifty-five who relapsed on BTKis were included analyzed. 31 had matched sequencing data. High sensitivity droplet digital PCR (ddPCR) was additionally used for detecting certain BTKC481S...